

# *Rheumatoid arthritis* *a holistic portfolio*

---



**with Anti-MCV**

to unlock the full potential  
of early diagnosis



**sebia** 

The new language of life

## Key features of Anti-MCV

- ELISA test for the quantitative measurement of IgG antibodies against **mutated citrullinated vimentin** (MCV)
- **Highly specific** (97%) and **extremely sensitive** (82%) marker for rheumatoid arthritis (RA)
- Can detect the disease at a **very early stage**, even in patients who test negative for rheumatoid factor and to some degree even before the appearance of specific clinical symptoms

## Random access solution for Screening and differentiation of rheumatoid arthritis


### Fully automated testing with Alegria 2

Flexible, reliable and efficient utilizing the Alegria Monotest technology.  
Customized, full patient profiles within one run.



### Or open systems

Complete portfolio also available as ELISA plates.



## Main benefits

**Improve RA diagnosis: Anti-MCV  
to fill the gap**

**1** Based on the antigen involved in the pathogenesis of RA

**2** MCV is a pathogenicity factor for RA and can induce bone destruction before the first appearance of specific symptoms



## A complete portfolio for the diagnosis of rheumatoid arthritis

Autoantibodies against citrullinated peptides/proteins (ACPA), e.g. anti-MCV and anti-CCP, and rheumatoid factor (RF) are essential components of the ACR/EULAR criteria for classification of rheumatoid arthritis.

### Anti-MCV

- Measurement of autoantibodies against mutated citrullinated vimentin
- Highly specific and extremely sensitive for RA

### Anti-CCP hs

- Tailored antigen profile for enhanced autoantibody recognition:  
Library of citrullinated peptides
- Numerous different epitopes for higher sensitivity

### Rheumatoid Factor IgM, IgA, IgG

- Quantitative measurement of individual RF isotypes
- IgM + IgA RF double positive is highly specific for RA



## Proven medical value

### Hundreds of publications highlighting:

- Increased sensitivity
- Correlation with disease activity
- Predictive value
- Prognostic capacity
- Benefit in diagnosis of early RA
- Potential use for therapy monitoring

# 3

Reliable early detection of RA supports rapid selection and implementation of treatment

# 4

Increased diagnostic sensitivity for early RA with Anti-MCV and comparable specificity

# Anti-MCV *in the literature*

- Zhu, Jia-Ning et al. "Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?" Clinical chemistry and laboratory medicine vol. 57,11 (2019): 1668-1679. doi:10.1515/cclm-2019-0167
- Barouta, Georgia et al. "Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis." Clinical rheumatology vol. 36,4 (2017): 885-894. doi:10.1007/s10067-016-3494-4
- Kuna, Andrea Tesija. "Mutated citrullinated vimentin antibodies in rheumatoid arthritis." Clinica chimica acta; international journal of clinical chemistry vol. 413,1-2 (2012): 66-73. doi:10.1016/j.cca.2011.10.020
- El-Barbary, Amal M et al. "Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide." The Journal of rheumatology vol. 38,5 (2011): 828-34. doi:10.3899/jrheum.101143
- Liu, Xia et al. "The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis." The Journal of rheumatology vol. 36,6 (2009): 1136-42. doi:10.3899/jrheum.080796
- Bang, Holger et al. "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis." Arthritis and rheumatism vol. 56,8 (2007): 2503-11. doi:10.1002/art.22817

## Further references

- Bertin, Daniel et al. "Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis." Immunologic research vol. 64,2 (2016): 455-60. doi:10.1007/s12026-015-8690-9
- Kay, Jonathan, and Katherine S Upchurch. "ACR/EULAR 2010 rheumatoid arthritis classification criteria." Rheumatology (Oxford, England) vol. 51 Suppl 6 (2012): vi5-9. doi:10.1093/rheumatology/kes279

## Ordering information

### Instrument

• Alegria 2.....ORG 320

### External Quality Controls

• Alegria - Check RHEUMA\*.....ORG 164-2x05  
Validated for ORG 222A, ORG 222M, ORG 301

### Accessories

• Alegria 300µl Automation Tips.....ORG 302

### Reagents

	Open system ELISA	Alegria
• Anti-MCV .....	ORG 548	ORG 248
• Anti-CCP hs .....	ORG 601	ORG 301
• Rheumatoid Factor IgM .....	ORG 522M	ORG 222M
• Rheumatoid Factor IgA .....	ORG 522A	ORG 222A
• Rheumatoid Factor IgG .....	ORG 522G	ORG 222G



Scan here  
for more information  
about Anti-MCV

For further information, please find your Sebia local representative to contact on our Website [www.sebia.com/sebia/worldwide-presence/](http://www.sebia.com/sebia/worldwide-presence/).



**ORGENTEC Diagnostika GmbH** | Carl-Zeiss-Straße 49-51 | 55129 Mainz | Deutschland | Tel. : +49 6131 / 9258-0 |  
Fax : +49 6131 / 9258-58 | E-mail : [orgentec@orgentec.com](mailto:orgentec@orgentec.com) | [www.orgentec.com](http://www.orgentec.com)

©Sebia2026 **ORGENTEC Diagnostika GmbH** - Carl-Zeiss-Straße 49-51 | 55129 Mainz | Deutschland - Ref. : QM211069 - MCVBIEN - 12/2024 - 02 - Non-contractual illustration  
ORGENTEC reserves the right to modify at any time and without notice the information contained in this document intended for healthcare professionals. This document contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Carefully read the instructions in the reagent package inserts and instrument manuals. \* **Theradiag** - 14 rue Ambroise Croizat | 77183 Croissy Beaubourg | France